Søeborg T, Frederiksen H, Andersson A M
Department of Growth and Reproduction, Section 5064, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Int J Androl. 2012 Jun;35(3):245-52. doi: 10.1111/j.1365-2605.2011.01240.x. Epub 2012 Feb 9.
Human risk assessment of chemicals is traditionally presented as the ratio between the actual level of exposure and an acceptable level of exposure, with the acceptable level of exposure most often being estimated by appropriate authorities. This approach is generally sound when assessing the risk of individual chemicals. However, several chemicals may concurrently target the same receptor, work through the same mechanism or in other ways induce the same effect(s) in the body. In these cases, cumulative risk assessment should be applied. The present study uses biomonitoring data from 129 Danish children and adolescents and resulting estimated daily intakes of four different phthalates. These daily intake estimates are used for a cumulative risk assessment with anti-androgenic effects as the endpoint using Tolerable Daily Intake (TDI) values determined by the European Food Safety Authorities (EFSA) or Reference Doses for Anti-Androgenicity (RfD AA) determined by Kortenkamp and Faust [Int J Androl 33 (2010) 463] as acceptable levels of exposure. United States Environmental Protection Agency Reference Doses (US EPA RfD) could not be used as none of them identifies anti-androgenic effects as the most sensitive endpoint for the phthalates included in this article. Using the EFSA TDI values, 12 children exceeded the hazard quotient for the sum of di-n-butyl phthalate and di-iso-butyl phthalate (∑DBP((i+n))) and one child exceeded the hazard quotient for di-(2-ethylhexyl)phthalate (DEHP). Nineteen children exceeded the cumulated hazard index for three phthalates. Using the RfD AA values, one child exceeded the hazard quotient for DEHP and the same child exceeded the cumulated hazard index for four phthalates. The EFSA TDI approach thus is more restrictive and identifies ∑DBP((i+n)) as the compound(s) associated with the greatest risk, while DEHP is the compound associated with the greatest risk when using the RfD AA approach.
传统上,化学品的人体风险评估是以实际暴露水平与可接受暴露水平之比来表示的,其中可接受暴露水平通常由相关当局估算。在评估单一化学品的风险时,这种方法总体上是合理的。然而,几种化学品可能同时作用于同一受体,通过相同机制或其他方式在体内产生相同的效应。在这些情况下,应进行累积风险评估。本研究使用了129名丹麦儿童和青少年的生物监测数据以及由此得出的四种不同邻苯二甲酸酯的估计每日摄入量。这些每日摄入量估计值用于以抗雄激素效应为终点的累积风险评估,使用欧洲食品安全局(EFSA)确定的每日耐受摄入量(TDI)值或由Kortenkamp和Faust [《国际男性学杂志》33 (2010) 463] 确定的抗雄激素性参考剂量(RfD AA)作为可接受暴露水平。美国环境保护局参考剂量(US EPA RfD)不能使用,因为它们均未将抗雄激素效应确定为本篇文章中所涉邻苯二甲酸酯最敏感的终点。使用EFSA TDI值时,12名儿童的邻苯二甲酸二丁酯和邻苯二甲酸二异丁酯总和(∑DBP((i+n)))的危害商超过限值,1名儿童的邻苯二甲酸二(2-乙基己基)酯(DEHP)的危害商超过限值。19名儿童的三种邻苯二甲酸酯的累积危害指数超过限值。使用RfD AA值时,1名儿童的DEHP危害商超过限值,且该儿童的四种邻苯二甲酸酯的累积危害指数也超过限值。因此,EFSA TDI方法更为严格,将∑DBP((i+n))确定为与最大风险相关的化合物,而使用RfD AA方法时,DEHP是与最大风险相关的化合物。